Jacobs Levy Equity Management
GNMK

Jacobs Levy Equity Management’s GenMark Diagnostics, Inc GNMK Stock Holding History

Jacobs Levy Equity Management’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-27,701
Closed -$393K – 1133
2020
Q3 		$393K Sell
27,701
-35,528
-56% -$543K ﹤0.01% 847
2020
Q2 		$930K Sell
63,229
-257,683
-80% -$2.62M 0.01% 682
2020
Q1 		$1.32M Buy
320,912
+75,794
+31% +$355K 0.02% 565
2019
Q4 		$1.18M Buy
245,118
+164,491
+204% +$907K 0.01% 658
2019
Q3 		$489K Buy
+80,627
New +$503K 0.01% 721
2019
Q1 		– Sell
-210,270
Closed -$1.02M – 1075
2018
Q4 		$1.02M Buy
210,270
+20,000
+11% +$104K 0.02% 592
2018
Q3 		$1.4M Buy
190,270
+17,023
+10% +$125K 0.02% 586
2018
Q2 		$1.1M Sell
173,247
-38,417
-18% -$254K 0.02% 642
2018
Q1 		$1.15M Sell
211,664
-42,036
-17% -$209K 0.02% 603
2017
Q4 		$1.06M Buy
+253,700
New +$1.53M 0.02% 604

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jacobs Levy Equity Management's GNMK Position: Q4 2020 in Review

Jacobs Levy Equity Management sold out of GenMark Diagnostics, Inc (GNMK) in Q4 2020, closing a stake of 27,701 shares — an estimated $393K sold.

Jacobs Levy Equity Management first reported a position in GNMK in Q4 2017 and held it in 10 quarters. The position peaked at $1.4M in Q3 2018. 151 funds tracked by Wall St. Rank hold GNMK as of Q4 2020.

  • Jacobs Levy Equity Management reported no remaining GenMark Diagnostics, Inc position as of Q4 2020 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 27,701 GenMark Diagnostics, Inc shares in Q4 2020, an estimated $393K.
  • Jacobs Levy Equity Management first reported a position in GenMark Diagnostics, Inc in Q4 2017 and held it in 10 quarters.
  • Jacobs Levy Equity Management's GenMark Diagnostics, Inc position peaked at $1.4M in Q3 2018.
  • 151 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q4 2020.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2020, filed 16 Feb 2021.